lead investigator discuss clinical trial combining echotherapy and imunotherapy to treat metastatic breast cancer

Theraclion SA

11/09/2017 07:31

Sept 11 (Reuters) - THERACLION SA  ALTHER.PA : 
    * THERACLION AND CO-LEAD INVESTIGATOR DISCUSS RATIONALE AND 
DESIGN OF FIRST CLINICAL TRIAL COMBINING ECHOTHERAPY AND 
IMUNOTHERAPY TO TREAT METASTATIC BREAST CANCER 
    * CLINICAL TRIAL IS EXPECTED TO BEGIN PATIENT ACCRUAL AT UVA 
IN OCTOBER 2017, AND WILL BE A TWO-ARM STUDY OF 12 PATIENTS 
    * CLINICAL TRIAL WILL BE A TWO-ARM STUDY OF 12 PATIENTS 
    * PEMBROLIZUMAB IS ABLE TO INDUCE AN IMMUNE RESPONSE TO 
SOME BREAST CANCERS AND HIFU ARE ABLE TO INDUCE AN IMMUNE 
RESPONSE IN MOST TUMORS, BUT NOT ENOUGH ON ITS OWN TO BE 
CURATIVE 
    * RATIONALE FOR CLINICAL STUDY IS THAT COMBINATION OF 
PEMBROLIZUMAB AND HIFU MIGHT BE MORE EFFECTIVE 
    * PRIMARY OBJECTIVES ARE TO ASSESS ADVERSE EVENT PROFILE OF 
PEMBROLIZUMAB AND FOCUSED ULTRASOUND THERAPY 
    * PRIMARY OBJECTIVES ARE TO DETERMINE OF ADDITION OF 
PEMBROLIZUMAB TO FOCUSED ULTRASOUND INCREASES PROPORTION OF CD8+ 
TUMOR INFILTRATING LYMPHOCYTES IN PRIMARY ABLATION ZONE 
    * SECONDARY OBJECTIVES ARE TO COMPARE CD8+ T-CELL RESPONSES 
AT PERI-ABLATION ZONES WHEN PEMBROLIZUMAB IS GIVEN BEFORE OR 
AFTER HIFU 
    * SECONDARY OBJECTIVES ARE TO EVALUATE PROGRESSION FREE AND 
OVERALL SURVIVAL 
 
Source text for Eikon:  ID:nBw3Gydf8a  
Further company coverage:  ALTHER.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))